Summary
Bristol Myers Squibb Company (BMY) has filed an 8-K report detailing a change in its Board of Directors. Mr. Dinesh Paliwal has informed the company that he will not seek re-election to the Board at the upcoming 2021 Annual Meeting of Shareholders. This departure, effective as of the meeting, will result in a reduction in the size of the Board from its current composition to ten directors. The 2021 Annual Meeting is scheduled to take place on May 4, 2021. This filing provides transparency regarding the composition of the company's leadership and governance structure moving forward.
Key Highlights
- 1Director Dinesh Paliwal will not stand for re-election to the Board of Directors at the 2021 Annual Meeting.
- 2Mr. Paliwal's departure will be effective as of the 2021 Annual Meeting of Shareholders.
- 3The Board of Directors' size has been set at ten members, effective from the 2021 Annual Meeting.
- 4The 2021 Annual Meeting of Shareholders is expected to be held on May 4, 2021.
- 5This filing primarily concerns changes in board composition and does not involve financial results or material operational updates.
Frequently Asked Questions
Mr. Dinesh Paliwal has notified Bristol Myers Squibb Company that he will not stand for re-election to the Board of Directors at the 2021 Annual Meeting of Shareholders. The filing does not provide specific reasons for his decision not to seek re-election.
Effective as of the 2021 Annual Meeting of Shareholders, the Board of Directors' size will be reduced to ten members.
The changes regarding the Board composition will be formalized at the 2021 Annual Meeting of Shareholders, which is expected to be held on May 4, 2021.